Although widely employed to treat high-grade glioma, the combination of irinotecan and the anti-VEGF antibody bevacizumab has shown no evidence to date of compelling activity in sarcoma in the limited studies to date [55, 56]. This evidence concerns the gene VEGFA and glioma.